Medibank Private Intrinsic Value Calculation – MEDIBANK PRIVATE Reports Second Quarter FY2023 Earnings Ending December 31 2022
March 13, 2023
Earnings Overview
MEDIBANK PRIVATE ($ASX:MPL) announced its second quarter FY2023 earnings results for the period ending December 31 2022. Revenue for the quarter was AUD 233.3 million, which is 5.9% higher than in the same period of the previous year. Net income was reported at AUD 3692.5 million, representing a 2.5% growth from the year before.
Stock Price
On Thursday, MEDIBANK PRIVATE reported their second quarter earnings for the fiscal year of 2023. The stock opened at AU$3.3 and closed at the same price, representing a 6.5% increase from the previous closing price of AU$3.1. This marks a positive turn for the company, indicating that investors have expressed confidence in its future performance. Given the current economic climate, these results indicate that the company is resilient and able to withstand financial hardship.
The company has made great strides over the past two quarters, including launching a new range of private health insurance products, expanding its presence in regional Australia, and introducing health and wellbeing initiatives for its customers. These efforts indicate that MEDIBANK PRIVATE is focused on providing quality service to its customers and meeting their needs. As MEDIBANK PRIVATE continues to grow, it is likely that their quarterly earnings report will remain positive. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medibank Private. More…
| Total Revenues | Net Income | Net Margin |
| 7.18k | 407 | 5.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medibank Private. More…
| Operations | Investing | Financing |
| 764 | -539.9 | -412.9 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medibank Private. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.2k | 2.23k | 0.72 |
Key Ratios Snapshot
Some of the financial key ratios for Medibank Private are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 2.6% | – | 8.1% |
| FCF Margin | ROE | ROA |
| 10.1% | 18.5% | 8.6% |
Analysis – Medibank Private Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of MEDIBANK PRIVATE‘s fundamentals. According to our proprietary Valuation Line, the intrinsic value of MEDIBANK PRIVATE share is estimated to be around AU$3.3. We believe that this analysis provides investors with an accurate and reliable gauge of the company’s true worth, and can help them make informed decisions when assessing their investment options. More…
Peers
In the insurance industry in Australia, there is high competition between Medibank Private Ltd and its competitors: NIB Holdings Ltd, Star Health and Allied Insurance Co Ltd, Discovery Ltd. All of these companies offer a variety of health insurance plans with different features and benefits.
However, Medibank Private Ltd is the largest provider of health insurance in Australia. It has a wide range of products and services, as well as a strong brand presence. The company also has a large customer base and a strong distribution network.
– NIB Holdings Ltd ($ASX:NHF)
NIB Holdings Ltd is an Australian company that provides health insurance products and services. The company has a market capitalization of $3.26 billion as of 2022 and a return on equity of 22.39%. NIB Holdings Ltd offers a range of health insurance products including hospital, extras, and ancillary cover. The company operates in Australia, New Zealand, and the United Kingdom.
– Star Health and Allied Insurance Co Ltd ($BSE:543412)
Star Health and Allied Insurance Co Ltd is a health insurance company with a market cap of 419.29B as of 2022. The company has a Return on Equity of -21.69%. The company offers health insurance products and services to individuals and businesses. The company operates in India and the United Arab Emirates.
– Discovery Ltd ($OTCPK:DCYHY)
The company’s market cap is 4.09B as of 2022. The company’s ROE is 10.75%. The company is involved in the discovery and development of new drugs and therapies.
Summary
MEDIBANK PRIVATE reported a strong quarter for the period ending December 31 2022 with total revenue of AUD 233.3 million and net income of AUD 3692.5 million, both representing healthy year-on-year growth of 5.9% and 2.5%, respectively. The news made a positive impact on the stock price, with an increase the same day. Investors may be further encouraged by the company’s ability to sustain growth and increase profits in an uncertain economic environment. As a result, MEDIBANK PRIVATE may be an attractive long-term investment option for those seeking a strong and reliable return.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
